GeneQuantum And BioMap Collaborate For Next-Gen ADC Therapeutics
GeneQuantum Healthcare (GQ) and BioMap have entered a
strategic collaboration to co-develop FIC/BIC ADC therapeutics, focusing on ADC
new drug development and innovative bioconjugation technologies. GQ's enzymatic
site-specific conjugation technology and linker-payload platform will merge
with BioMap's life science AI Foundation, including the trillion-parameter
Large Language Model xTrimo and AI protein generation platform AIGP. The
collaboration aims to create novel ADCs addressing high unmet medical needs by
leveraging GQ's expertise in ADC drug development and BioMap's capabilities in
target recommendation, high-performance antibody design, and AI-driven
solutions. The partnership seeks to enhance R&D efficiency, reduce
development costs, and accelerate the development of breakthrough ADC
therapeutics, contributing to a new paradigm in global ADC drug development.
Dr. Gang Qin, Founder and Chairman of GQ, expressed the
shared commitment to disruptive innovation, emphasizing collaborative synergy
to address global medical needs. Vicky Qu, Senior VP of BioMap, highlighted
their Foundation Model's potential and the goal to improve ADC drug safety and
efficacy through precise disease selection. The collaboration reflects a
strategic approach to advance ADC drug development by integrating each
partner's strengths and fostering generative capabilities in life science
R&D scenarios.
More Information : https://www.techdogs.com/tech-news/pr-newswire/genequantum-and-biomap-establish-a-strategic-collaboration-to-jointly-develop-a-series-of-next-generation-adc-therapeutics
Comments
Post a Comment